PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22461168-7 2009 As compared to the placebo period, raloxifene treatment decreased the response to an oral calcium load, together with a decrease in 1,25(OH)(2)D(3) and in IGF-I serum levels. Raloxifene Hydrochloride 35-45 insulin like growth factor 1 Homo sapiens 155-160 22461168-10 2009 These results are compatible with the hypothesis that raloxifene is associated with lower IGF-I and 1,25(OH)(2)D(3) levels, with consequently reduced intestinal calcium absorption capacity. Raloxifene Hydrochloride 54-64 insulin like growth factor 1 Homo sapiens 90-101 17645796-8 2007 This reduction in serum IGF-I levels following treatment with raloxifene was statistically significant (p < 0.001). Raloxifene Hydrochloride 62-72 insulin like growth factor 1 Homo sapiens 24-29 18193094-8 2008 In contrast, although raloxifene increased the binding of ERalpha to the AP1 site of the promoters of c-Myc and IGF-1, raloxifene had no effect on the gene expression of c-Myc or IGF-1. Raloxifene Hydrochloride 22-32 insulin like growth factor 1 Homo sapiens 112-117 18193094-9 2008 Raloxifene induced the recruitment of co-repressors such as HDAC2, N-CoR and SMRT to the promoter of IGF-1. Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 101-106 17872375-7 2007 Treatment with E(2) or raloxifene increased both IGF-I and cyclooxygenase (COX)-2 mRNA expression in HUVECs, whereas they attenuated the serum-induced increase of these genes in HASMCs. Raloxifene Hydrochloride 23-33 insulin like growth factor 1 Homo sapiens 49-54 17872375-8 2007 Treatment by E(2) and raloxifene induced recruitment of coactivator complex and histone acetylation at both the IGF-I and COX-2 gene promoter in HUVECs. Raloxifene Hydrochloride 22-32 insulin like growth factor 1 Homo sapiens 112-117 17872375-9 2007 In contrast, in HASMCs, E(2), and raloxifene attenuated the serum-induced recruitment of coactivator complexes and histone acetylation at both the IGF-I and COX-2 gene promoters. Raloxifene Hydrochloride 34-44 insulin like growth factor 1 Homo sapiens 147-152 17872375-10 2007 Estrogen and raloxifene exert divergent transcriptional regulation on both mRNA expression and the remodeling of IGF-I and COX-2 gene promoters in HUVECs vs. HASMCs. Raloxifene Hydrochloride 13-23 insulin like growth factor 1 Homo sapiens 113-118 17645796-0 2007 Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene. Raloxifene Hydrochloride 99-109 insulin like growth factor 1 Homo sapiens 14-42 17645796-1 2007 BACKGROUND: The objective of this study was to evaluate serum IGF-I levels in postmenopausal women with breast cancer treated primarily with raloxifene. Raloxifene Hydrochloride 141-151 insulin like growth factor 1 Homo sapiens 62-67 17645796-7 2007 RESULTS: Mean serum IGF-I levels pre- and post-raloxifene treatment were 143.7 +/- 9.7 ng/ml and 94.8 +/- 7.6 ng/ml, respectively. Raloxifene Hydrochloride 47-57 insulin like growth factor 1 Homo sapiens 20-25 17645796-9 2007 CONCLUSION: Raloxifene significantly reduced serum IGF-I levels in postmenopausal women with breast cancer. Raloxifene Hydrochloride 12-22 insulin like growth factor 1 Homo sapiens 51-56 16912660-13 2006 Moreover, raloxifene treatment significantly reduced IGF-1 and increased IGFBP-3 and SHBG plasma levels at 24 months. Raloxifene Hydrochloride 10-20 insulin like growth factor 1 Homo sapiens 53-58 16912660-16 2006 Such an effect could perhaps explain the reduction in the incidence of mammary carcinoma observed in the Multiple Outcomes of Raloxifene Evaluation study probably due to the direct antiestrogenic activity of raloxifene on mammalian tissue and/or its indirect activity increasing SHBG levels or modifying the IGF-1/IGFBP-3 ratio. Raloxifene Hydrochloride 208-218 insulin like growth factor 1 Homo sapiens 308-313 15876410-1 2005 We have tested the effects of two Eli-Lilly compounds, LY 117, 018 and raloxifene, on E2-regulated and IGF-I-induced proliferation or AP-1 activity in human breast cancer cells. Raloxifene Hydrochloride 71-81 insulin like growth factor 1 Homo sapiens 103-108 15978972-14 2005 CONCLUSION: Both raloxifene and oral testosterone increased serum testosterone, but raloxifene significantly decreased serum IGF-1 levels without affecting IGFBP-3. Raloxifene Hydrochloride 84-94 insulin like growth factor 1 Homo sapiens 125-130 15855258-10 2005 Raloxifene reduced IGF-I levels in the GHD group (P < 0.001), but not in the postmenopausal group. Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 19-24 16098853-1 2005 OBJECTIVE: The purpose of this study was to investigate the effect of raloxifene on leptin and insulin-like growth factor-I levels and their relation with the biochemical markers of bone metabolism in postmenopausal women. Raloxifene Hydrochloride 70-80 insulin like growth factor 1 Homo sapiens 95-123 16098853-6 2005 Raloxifene therapy increased leptin levels (P < .001) and decreased insulin-like growth factor-I, alkaline phosphatase, and cross-link C-telopeptide levels significantly (P < .001). Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 71-99 15978972-2 2005 The partial oestrogen agonist and antagonist raloxifene increase serum testosterone levels in aging men, but the effect of raloxifene on serum IGF-1 levels in men is unknown. Raloxifene Hydrochloride 123-133 insulin like growth factor 1 Homo sapiens 143-148 15978972-3 2005 In this study the effects of raloxifene on IGF-1 levels and the associated increase in serum testosterone were compared to the effects of oral testosterone supplementation. Raloxifene Hydrochloride 29-39 insulin like growth factor 1 Homo sapiens 43-48 15978972-8 2005 RESULTS: Compared to placebo raloxifene increased serum testosterone by 20% but it decreased serum IGF-1 levels by 24.5% (95% confidence interval (CI): -13.0 to -36.1%). Raloxifene Hydrochloride 29-39 insulin like growth factor 1 Homo sapiens 99-104 15978972-10 2005 The effect of raloxifene on serum IGF-1 has been observed with other oral oestrogens, and, therefore, is likely to be ascribed to the partial oestrogen agonist activity of raloxifene. Raloxifene Hydrochloride 14-24 insulin like growth factor 1 Homo sapiens 34-39 15978972-10 2005 The effect of raloxifene on serum IGF-1 has been observed with other oral oestrogens, and, therefore, is likely to be ascribed to the partial oestrogen agonist activity of raloxifene. Raloxifene Hydrochloride 172-182 insulin like growth factor 1 Homo sapiens 34-39 15876410-4 2005 Moreover, raloxifene was the most efficient molecule to prevent IGF-I-induced AP-1 activity, with a significant effect observed with a concentration as low as 5 x 10(-11)M in the presence of IGF-I alone. Raloxifene Hydrochloride 10-20 insulin like growth factor 1 Homo sapiens 64-69 15876410-4 2005 Moreover, raloxifene was the most efficient molecule to prevent IGF-I-induced AP-1 activity, with a significant effect observed with a concentration as low as 5 x 10(-11)M in the presence of IGF-I alone. Raloxifene Hydrochloride 10-20 insulin like growth factor 1 Homo sapiens 191-196 15876410-8 2005 Our data altogether demonstrate that raloxifene has a potent inhibitory effect on IGF-I action, with a drastic effect on AP-1 triggered responses as well as on Akt phosphorylation, suggesting that it might be a useful therapeutic agent in tumors in which these signalling pathways become constitutively active. Raloxifene Hydrochloride 37-47 insulin like growth factor 1 Homo sapiens 82-87 15762036-0 2004 Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. Raloxifene Hydrochloride 43-53 insulin like growth factor 1 Homo sapiens 144-172 15762036-4 2004 Gene expression of IGF-I increased following 24 or 30 h incubation with 10(-8) M 17beta-estradiol and 30 h incubation with raloxifene. Raloxifene Hydrochloride 123-133 insulin like growth factor 1 Homo sapiens 19-24 15762036-8 2004 On the other hand, an increase in IGF-I synthesis induced by raloxifene and estradiol could mediate, in part, the effects of these compounds on bone. Raloxifene Hydrochloride 61-71 insulin like growth factor 1 Homo sapiens 34-39 34384975-6 2021 Raloxifene therapy significantly reduced IGF-1 levels (WMD: -2.92 nmol/L, 95% CI: -3.49, -2.35, p < 0.001) compared to placebo. Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 41-46 15302288-11 2004 CONCLUSION(S): Long-term use of both CEE and raloxifene decreases serum IGF-I and the IGF-I/IGFBP-3 ratio, but, unlike CEE, raloxifene produced a significant yet small increase in IGFBP-3. Raloxifene Hydrochloride 45-55 insulin like growth factor 1 Homo sapiens 86-91 12656665-0 2003 Raloxifene lowers IGF-I levels in acromegalic women. Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 18-23 11747323-0 2001 Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Raloxifene Hydrochloride 10-20 insulin like growth factor 1 Homo sapiens 24-29 11747323-2 2001 Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 63-68 11747323-4 2001 Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention. Raloxifene Hydrochloride 164-174 insulin like growth factor 1 Homo sapiens 33-38 11397884-16 2001 At 0 h, raloxifene use was associated with lower IGF-I/IGFBP-3 ratio (4.3 +/- 0.7 vs. 2.9 +/- 0.7 and 3.0 +/- 0.7 nmol/mg; P = 0.001) and insulin/glucose ratio (13.7 +/- 5.2 vs. 11.9 +/- 5.9 and 9.5 +/- 2.3 pmol/mmol; P = 0.04). Raloxifene Hydrochloride 8-18 insulin like growth factor 1 Homo sapiens 49-54 11397884-17 2001 Similarly, raloxifene use was associated with lower IGF-I/IGFBP-3 and insulin/glucose ratios at 24 h (P = 0.01 and 0.07). Raloxifene Hydrochloride 11-21 insulin like growth factor 1 Homo sapiens 52-57 15302288-1 2004 OBJECTIVE: To assess and compare the effect of conjugated estrogen and of the selective estrogen receptor modulator raloxifene on serum levels of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) and on the IGF-I/IGFBP-3 ratio. Raloxifene Hydrochloride 116-126 insulin like growth factor 1 Homo sapiens 146-174 15302288-1 2004 OBJECTIVE: To assess and compare the effect of conjugated estrogen and of the selective estrogen receptor modulator raloxifene on serum levels of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) and on the IGF-I/IGFBP-3 ratio. Raloxifene Hydrochloride 116-126 insulin like growth factor 1 Homo sapiens 176-181 15302288-7 2004 RESULT(S): Both raloxifene and CEE decreased serum IGF-I concentration. Raloxifene Hydrochloride 16-26 insulin like growth factor 1 Homo sapiens 51-56 15302288-9 2004 Compared with placebo, the decrease in IGF-I/IGFBP-3 ratio was -32.5% (95% CI: -20.1; -44.8%) for CEE; -16.4% (95% CI: -3.6; -29.2%) for raloxifene at 150 mg/day; and -15.4% (95% CI: -1.0; -29.8%) for raloxifene at 60 mg/day. Raloxifene Hydrochloride 137-147 insulin like growth factor 1 Homo sapiens 39-44 15302288-9 2004 Compared with placebo, the decrease in IGF-I/IGFBP-3 ratio was -32.5% (95% CI: -20.1; -44.8%) for CEE; -16.4% (95% CI: -3.6; -29.2%) for raloxifene at 150 mg/day; and -15.4% (95% CI: -1.0; -29.8%) for raloxifene at 60 mg/day. Raloxifene Hydrochloride 201-211 insulin like growth factor 1 Homo sapiens 39-44 15302288-11 2004 CONCLUSION(S): Long-term use of both CEE and raloxifene decreases serum IGF-I and the IGF-I/IGFBP-3 ratio, but, unlike CEE, raloxifene produced a significant yet small increase in IGFBP-3. Raloxifene Hydrochloride 45-55 insulin like growth factor 1 Homo sapiens 72-77 15080777-0 2004 Raloxifene decreases serum IGF-I in male patients with active acromegaly. Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 27-32 15080777-10 2004 RESULTS: Raloxifene did not affect basal GH secretion or response of GH to TRH, GHRH or glucose, but it decreased circulating IGF-I by 16+/-4% (P=0.001), and normalized plasma IGF-I in two patients. Raloxifene Hydrochloride 9-19 insulin like growth factor 1 Homo sapiens 126-131 11457856-5 2001 Transfer of IGF-I promoter sequences from -733 to -65 or from -375 to -65 to a minimal Fos promoter resulted in a comparable responsiveness to raloxifene. Raloxifene Hydrochloride 143-153 insulin like growth factor 1 Homo sapiens 12-17 34384975-0 2021 Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials. Raloxifene Hydrochloride 11-21 insulin like growth factor 1 Homo sapiens 56-84 34384975-1 2021 OBJECTIVE: To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels. Raloxifene Hydrochloride 50-60 insulin like growth factor 1 Homo sapiens 79-107 34384975-1 2021 OBJECTIVE: To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels. Raloxifene Hydrochloride 50-60 insulin like growth factor 1 Homo sapiens 109-114 34384975-7 2021 Raloxifene dosage 60 mg/day (WMD: -3.29 ng/mL, 95% CI: -3.50 to -3.08, I2 = 0.0%) decreased IGF-1 levels more than 60 mg/day (WMD: -2.29 ng/mL, 95% CI: -2.90 to -1.69, I2 = 16%). Raloxifene Hydrochloride 0-10 insulin like growth factor 1 Homo sapiens 93-98 34384975-10 2021 CONCLUSION: Raloxifene therapy significantly reduced serum levels of IGF-1 levels but without changes in IGFPB-3 levels. Raloxifene Hydrochloride 12-22 insulin like growth factor 1 Homo sapiens 69-74 29949429-6 2018 RESULTS: Serum IGF-1 was significantly decreased in both the cabergoline (40.3 +- 25.6%, P<.001) and raloxifene (31.5 +- 24.6%, P<.001) groups, with no significant difference between arms ( P>.05). Raloxifene Hydrochloride 104-114 insulin like growth factor 1 Homo sapiens 15-20 29949429-11 2018 CONCLUSION: Cabergoline and raloxifene add-on therapy could effectively decrease serum IGF-1 level in patients with inadequately controlled acromegaly. Raloxifene Hydrochloride 28-38 insulin like growth factor 1 Homo sapiens 87-92 24347426-0 2014 Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women. Raloxifene Hydrochloride 11-21 insulin like growth factor 1 Homo sapiens 48-52 24347426-14 2014 CONCLUSION: Raloxifene effect on bioactive IGF1 is similar to that of estrogen despite higher IGFBP3 levels during raloxifene administration. Raloxifene Hydrochloride 12-22 insulin like growth factor 1 Homo sapiens 43-47 24347426-2 2014 During GH therapy in hypopituitary women, co-treatment with raloxifene, a SERM, induced a smaller gain in lean body mass (LBM) compared with estrogen, despite an equal reduction in IGF1. Raloxifene Hydrochloride 60-70 insulin like growth factor 1 Homo sapiens 181-185 24347426-3 2014 As a higher IGF-binding protein-3 (IGFBP3) level was observed with raloxifene co-treatment, we hypothesize that an increase in IGFBP3 reduced IGF1 bioactivity causing the attenuated anabolic effect. Raloxifene Hydrochloride 67-77 insulin like growth factor 1 Homo sapiens 142-146 24347426-4 2014 OBJECTIVE: To assess the effects of 17beta-estradiol (E2) and raloxifene on bioactive IGF1. Raloxifene Hydrochloride 62-72 insulin like growth factor 1 Homo sapiens 86-90 24347426-10 2014 GH significantly increased IGF1 bioactivity, an effect attenuated by co-treatment with raloxifene (Delta -23 +- 7%, P<0.01) and estrogen (Delta -26 +- 3%, P=0.06). Raloxifene Hydrochloride 87-97 insulin like growth factor 1 Homo sapiens 27-31 20843951-6 2010 OBJECTIVE: The aim was to compare the impact of raloxifene and tamoxifen on GH-IGF-I and gonadal axes in healthy men. Raloxifene Hydrochloride 48-58 insulin like growth factor 1 Homo sapiens 79-84 22319035-3 2012 Tamoxifen and raloxifene are selective estrogen receptor modulators (SERMs), drugs that block central estrogen action but exert estrogen-like effects in the liver, inhibiting hepatic IGF-I production. Raloxifene Hydrochloride 14-24 insulin like growth factor 1 Homo sapiens 183-188